Dixon Technologies shares fell on Monday despite posting a strong Q2 results, with net profit up 81% YoY to Rs 746 crore. Analysts at Motilal Oswal and JM Financial remain positive on long-term growth, citing strong mobile and EMS performance, but caution near-term margin pressure due to component ramp-up and cost integration.
Corona Remedies and Wakefit Innovations to list tomorrow; GMP suggests sharp upside for pharma play
Corona Remedies and Wakefit Innovations are set to list amid divergent grey market signals. Corona Remedies commands strong listing expectations backed by robust subscriptions and